Clear cell renal cell carcinoma (ccRCC) is one of the most common renal malignancies of
the urinary system. Patient outcomes are relatively poor due to the lack of early diagnostic …

Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited;
however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment …

Objectives This study aimed to assess the prognostic outcomes in mRCC patients receiving
second‐line TKI following first‐line IO combination therapy. Methods This study …

Background Although a combination of immune checkpoint inhibitors (ICIs) is recommended
as the first line treatment option for metastatic renal cell carcinoma (mRCC), several immune …

Over the last decades, the therapeutic armamentarium of metastatic renal cell carcinoma
(mRCC) has been revolutionized by the advent of tyrosin-kinase inhibitors (TKI), immune …

Background: Identifying optimal doses in early-phase clinical trials is critically important.
Therapies administered at doses that are either unsafe or biologically ineffective are unlikely …

While incidence rates of renal cancer have been steadily increasing, including a slow rise
over the past decade, mortality rates have slowly declined. 1, 2 This can be explained in part …

Background PET/CT imaging with Zirconium-89 labeled [89Zr] Zr-DFO-girentuximab, which
targets tumor antigen CAIX, may aid in the differentiation and characterization of clear cell …

Background To date, no studies have compared the treatment outcomes of second-line
therapies in patients with metastatic clear cell renal cell carcinoma (ccRCC). This study …

Background/Aim: Although the adverse events (AEs) of drugs, such as sunitinib and axitinib,
have been shown to predict treatment responses, evidence to support cabozantinib-induced …